Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03501134 · ClinicalTrials.gov registry record
Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 20
- Enrollment target
NCT03501134 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 20 participants.
The verdict
NCT03501134 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).
Interventions
- DEVICE NovoTTF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2021-06-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03501134
The ClinicalTrials.gov registry entry for NCT03501134 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NovoTTF is the first listed.
NCT03501134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03501134 about?
NCT03501134 is a clinical study titled "Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields". This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is ...
What is the current status of trial NCT03501134?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2018-08-08. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT03501134?
The interventions under investigation include: NovoTTF (DEVICE).
Who is sponsoring clinical trial NCT03501134?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.